Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00147199 · ClinicalTrials.gov registry record · Phase 3
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
A Phase 3 study of Pulmonary Hypertension, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 235
- Enrollment target
- 20
- Study locations
NCT00147199 is a Phase 3 study of Pulmonary Hypertension that has completed, run by United Therapeutics. The registered enrollment target is 235 participants, below the 610-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT00147199, a Phase 3 study of Pulmonary Hypertension, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 235 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a double-blind placebo-controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension. The primary outcome is the change in 6-minute walk distance from baseline to week 12.
Conditions Studied
Interventions
- DRUG Inhaled treprostinil
- DRUG Placebo inhalation solution
Study Locations (20)
Other
- Medical University Graz - Graz
- Universite Libre de Bruxelles - Brussels
- University Hospital Gasthuisburg - Leuven
- Hospital Antoine Beclere - Paris
California
- UCSD Medical center - La Jolla
- UCLA Medical Center - Torrance
Alabama
- University of Alabama - Birmingham
Arizona
- University of Arizona - Tucson
Colorado
- University of Colorado - Aurora
Florida
- Orlando Heart Center - Orlando
Kansas
- Kansas University Medical Center - Kansas City
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00147199
The ClinicalTrials.gov registry entry for NCT00147199 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 610-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (61% lower). The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Inhaled treprostinil is the first listed.
NCT00147199 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT00147199 about?
NCT00147199 is a clinical study titled "Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)". This is a double-blind placebo-controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension. The primary outcome is the change in 6-minute walk distance from baseline to week 12.
What is the current status of trial NCT00147199?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 235 participants. The study started on 2005-06. Estimated completion is 2007-10.
What conditions does trial NCT00147199 study?
This clinical trial studies the following conditions: Pulmonary Hypertension.
What interventions are being tested in trial NCT00147199?
The interventions under investigation include: Inhaled treprostinil (DRUG), Placebo inhalation solution (DRUG).
Who is sponsoring clinical trial NCT00147199?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00147199 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RECRUITING · Phase 3
-
Safety and Efficacy of FETO in CDH Phase III
RECRUITING · Phase 3
-
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
COMPLETED · Phase 3
-
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
COMPLETED · Phase 3
-
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.